By Counterforce Health Team in Opfolda (miglustat) —

How to Get Opfolda (miglustat) Covered by Cigna in Michigan: Complete PA Guide and Appeal Process

Answer Box: Getting Opfolda (miglustat) Covered by Cigna in Michigan

Eligibility: Adults ≥18 years, >40 kg with late-onset Pompe disease who haven't improved after ≥1 year on Lumizyme or Nexviazyme. Must be prescribed with Pombiliti (combination therapy only).

Fastest approval path: 1) Submit prior authorization via CoverMyMeds or call 1-800-882-4462, 2) Include ERT failure documentation and weight-based dosing plan, 3) Enroll with Accredo specialty pharmacy.

Start today: Contact your prescriber to gather ERT history, current pulmonary function tests, and 6-minute walk test results. Michigan residents have strong appeal rights through DIFS if initially denied.

Table of Contents

Coverage Requirements at a Glance

Requirement Details Where to Find It
Prior Authorization Required for all Cigna plans Cigna PA Policy IP_0598
Age & Weight ≥18 years and >40 kg (88 lbs) FDA labeling, Cigna policy
Diagnosis Late-onset Pompe disease (ICD-10: E74.02) Confirmed by enzyme assay or genetic testing
Step Therapy Must fail ≥1 year of Lumizyme or Nexviazyme Document lack of improvement in FVC/6MWT
Combination Use Only with Pombiliti; Opfolda alone is denied Cigna Pombiliti Policy
Specialty Pharmacy Accredo required Cigna Specialty Pharmacy Guide
Appeals Deadline 180 days internal; 127 days external (Michigan) Michigan DIFS

Step-by-Step: Fastest Path to Approval

1. Verify Coverage and Benefits

Who: Patient or clinic staff
Action: Call Cigna member services at 1-800-997-1654 to confirm specialty pharmacy benefits and PA requirements
Timeline: 15-30 minutes

2. Gather Required Documentation

Who: Prescribing physician
Documents needed:

  • ERT failure documentation (≥1 year Lumizyme/Nexviazyme with objective measures)
  • Current weight and vital signs
  • Confirmatory labs or genetic testing results
  • Pulmonary function tests and 6-minute walk test results

3. Submit Prior Authorization

Who: Prescriber or clinic staff
Method: CoverMyMeds portal or call 1-800-882-4462
Timeline: Standard review 1-3 business days
Source: Cigna PA Resources

4. Coordinate Pombiliti Prescription

Who: Prescriber
Action: Submit separate PA for Pombiliti (20 mg/kg IV every 2 weeks)
Note: Both medications must be approved together for coverage

5. Enroll with Accredo Specialty Pharmacy

Who: Patient with clinic support
Contact: MyAccredoPatients.com or 1-800-803-2523
Timeline: 2-3 business days for enrollment

6. Schedule Treatment

Who: Clinic and patient
Dosing: Weight-based every 2 weeks

  • 40-<50 kg: 195 mg (3 capsules) 1 hour before Pombiliti infusion
  • ≥50 kg: 260 mg (4 capsules) 1 hour before Pombiliti infusion

7. Monitor and Document Response

Who: Prescriber
Action: Track pulmonary function, 6MWT, and muscle strength for annual reauthorization

Required Documentation

Essential for PA approval:

  • Diagnosis confirmation: Enzyme assay showing acid alpha-glucosidase deficiency OR genetic testing with pathogenic GAA mutations
  • ERT failure evidence: Detailed records showing ≥1 year of optimized Lumizyme or Nexviazyme therapy with documented lack of improvement in:
    • Forced vital capacity (FVC) measurements
    • 6-minute walk test (6MWT) distance
    • Muscle strength assessments
  • Current clinical status: Weight, vital signs, functional assessments
  • Treatment plan: Weight-based Opfolda dosing coordinated with Pombiliti infusions
Tip: Request copies of all pulmonary function tests and 6MWT results from the past 18 months to demonstrate ERT inadequacy.

Submission Portals and Forms

Electronic Prior Authorization (Preferred)

Phone Submission

  • Provider line: 1-800-882-4462 (for providers unable to use electronic systems)
  • Member services: 1-800-997-1654 (for benefit verification)

Fax and Mail (If Electronic Unavailable)

  • Contact Cigna at 1-800-882-4462 to obtain current fax numbers and forms
  • Include cover sheet with patient ID, provider NPI, and urgency level

Common Denial Reasons & How to Fix Them

Denial Reason Solution Required Documentation
Requested as monotherapy Resubmit with Pombiliti combination Coordinate both PAs simultaneously
Insufficient ERT trial Document ≥1 year optimized therapy Serial FVC/6MWT results showing decline/plateau
Missing weight criteria Confirm patient >40 kg Current weight documentation
Age requirement not met Verify patient ≥18 years Date of birth confirmation
Inadequate diagnosis documentation Provide confirmatory testing Enzyme assay or genetic test results
Timing/dosing concerns Clarify administration protocol Weight-based dosing plan 1 hour before infusion

Appeals Process for Michigan Residents

Internal Appeals (First Level)

Deadline: 180 days from denial notice
Contact: Cigna member services 1-800-244-6224
Timeline: Standard 30 days; expedited 72 hours with physician support

External Review (Michigan DIFS)

Deadline: 127 days after final internal appeal denial
Portal: Michigan DIFS External Review
Phone: 877-999-6442
Timeline: 60 days standard; 72 hours expedited

Required for external review:

  • Completed FIS 0018 form (download from Michigan DIFS)
  • Copy of Cigna denial letter
  • Medical records supporting necessity
  • For expedited: Physician letter stating health jeopardy
Note: Michigan's external review decisions are binding on Cigna. The Independent Review Organization assigned by DIFS will have medical experts familiar with rare diseases.

Clinician Corner: Medical Necessity Letter

Essential components for Cigna PA approval:

  1. Patient demographics: Age ≥18, weight >40 kg, confirmed LOPD diagnosis (ICD-10: E74.02)
  2. Diagnostic confirmation: "Pompe disease confirmed by [enzyme assay showing acid alpha-glucosidase deficiency / genetic testing revealing pathogenic GAA mutations]"
  3. ERT failure documentation: "Despite ≥1 year of optimized [Lumizyme/Nexviazyme] therapy at [dose] mg/kg every 2 weeks, patient demonstrates inadequate response with [specific measures]:
    • FVC decline from [X]% to [Y]% predicted
    • 6MWT distance [unchanged/decreased] at [Z] meters
    • Muscle strength [specific measurements]"
  4. Combination rationale: "Per FDA labeling, Opfolda has no pharmacological activity as monotherapy and is only effective when combined with Pombiliti"
  5. Dosing plan: Weight-based dosing every 2 weeks, 1 hour before Pombiliti infusion
  6. Monitoring plan: Serial pulmonary function tests, 6MWT, and muscle strength assessments

Template opening: "[Patient] is a [age]-year-old, [weight] kg adult with confirmed late-onset Pompe disease (E74.02) who has demonstrated inadequate response to enzyme replacement therapy and meets all criteria for Opfolda/Pombiliti combination therapy per Cigna policy IP_0598."

Cost Considerations

Cigna coverage: Specialty tier 4/5 with high copays/coinsurance
Manufacturer support: Amicus Assist provides copay assistance and case management
Foundation grants: National Organization for Rare Disorders (NORD) and other rare disease foundations may offer financial assistance

From our advocates: We've seen patients successfully reduce out-of-pocket costs by combining manufacturer copay cards with foundation grants. Start the financial assistance applications early—some programs have waiting lists, and having multiple options approved gives you flexibility when treatment begins.

FAQ

How long does Cigna PA take for Opfolda in Michigan?
Standard review: 1-3 business days. Expedited review: 24 hours with physician support for urgent cases.

What if Opfolda is non-formulary on my Cigna plan?
Submit a formulary exception request through your physician, citing medical necessity and ERT failure. Cigna formulary exception process allows overrides with clinical justification.

Can I request an expedited appeal in Michigan?
Yes, if your physician certifies that waiting would jeopardize your health. Contact Cigna for expedited internal appeal, then DIFS for expedited external review if needed.

Does step therapy apply if I failed ERT outside Michigan?
Yes, Cigna accepts documented ERT failure from any provider. Ensure you have complete records showing ≥1 year of optimized therapy with objective measures.

What happens if Cigna denies my external review appeal?
Michigan's external review decisions are binding. If denied, explore formulary exceptions, seek second opinions, or consider clinical trials through ClinicalTrials.gov.

How often do I need reauthorization?
Annual reauthorization required with documentation of continued medical necessity and treatment response.

At Counterforce Health, we help patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals by identifying the specific denial basis and crafting evidence-backed rebuttals aligned to each plan's requirements. Our platform streamlines the complex prior authorization process for specialty medications like Opfolda, helping ensure patients get the treatments they need without unnecessary delays.

For additional support navigating Cigna's prior authorization process or appealing denials, Counterforce Health provides targeted assistance with payer-specific workflows and evidence compilation.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and requirements may change. Always verify current requirements with Cigna and consult with your healthcare provider for medical decisions. For assistance with insurance appeals in Michigan, contact the Department of Insurance and Financial Services at 877-999-6442.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.